365 related articles for article (PubMed ID: 14974009)
1. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (1):CD003189. PubMed ID: 14974009
[TBL] [Abstract][Full Text] [Related]
2. Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2002; (4):CD003189. PubMed ID: 12519588
[TBL] [Abstract][Full Text] [Related]
3. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474
[TBL] [Abstract][Full Text] [Related]
4. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Herbst C; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD003189. PubMed ID: 18843642
[TBL] [Abstract][Full Text] [Related]
5. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review.
Bohlius J; Reiser M; Schwarzer G; Engert A
Br J Haematol; 2003 Aug; 122(3):413-23. PubMed ID: 12877668
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
7. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy.
Herbst C; Naumann F; Kruse EB; Monsef I; Bohlius J; Schulz H; Engert A
Cochrane Database Syst Rev; 2009 Jan; (1):CD007107. PubMed ID: 19160320
[TBL] [Abstract][Full Text] [Related]
9. G-CSF and GM-CSF for treating or preventing neonatal infections.
Carr R; Modi N; Doré C
Cochrane Database Syst Rev; 2003; 2003(3):CD003066. PubMed ID: 12917944
[TBL] [Abstract][Full Text] [Related]
10. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia.
Sasse EC; Sasse AD; Brandalise S; Clark OA; Richards S
Cochrane Database Syst Rev; 2005 Jul; (3):CD004139. PubMed ID: 16034921
[TBL] [Abstract][Full Text] [Related]
11. Colony-stimulating factors for chemotherapy-induced febrile neutropenia.
Mhaskar R; Clark OA; Lyman G; Engel Ayer Botrel T; Morganti Paladini L; Djulbegovic B
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD003039. PubMed ID: 25356786
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes.
Hutzschenreuter F; Monsef I; Kreuzer KA; Engert A; Skoetz N
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009310. PubMed ID: 26880256
[TBL] [Abstract][Full Text] [Related]
13. Colony stimulating factors for chemotherapy induced febrile neutropenia.
Clark OA; Lyman G; Castro AA; Clark LG; Djulbegovic B
Cochrane Database Syst Rev; 2003; (3):CD003039. PubMed ID: 12917942
[TBL] [Abstract][Full Text] [Related]
14. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
Kuderer NM; Dale DC; Crawford J; Lyman GH
J Clin Oncol; 2007 Jul; 25(21):3158-67. PubMed ID: 17634496
[TBL] [Abstract][Full Text] [Related]
15. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
16. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
17. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
19. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
20. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.
van Dalen EC; Mank A; Leclercq E; Mulder RL; Davies M; Kersten MJ; van de Wetering MD
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD006247. PubMed ID: 27107610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
